Have a personal or library account? Click to login
A headspace-gas chromatography method for isopropanol determination in warfarin sodium products as a measure of drug crystallinity Cover

A headspace-gas chromatography method for isopropanol determination in warfarin sodium products as a measure of drug crystallinity

Acta Pharmaceutica
Volume 68 (2018): Issue 1 (March 2018)
By:
Open Access
|Feb 2018

References

  1. 1. G. Levy, What are narrow therapeutic index drugs? Clin. Pharmacol. Ther. 63 (1998) 501-505; <a href="https://doi.org/10.1016/S0009-9236(98)90100-X" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S0009-9236(98)90100-X</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1016/S0009-9236(98)90100-X" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S0009-9236(98)90100-X</a></dgdoi:pub-id>
    Search in Google ScholarBack to article
  2. 2. L. X. Yu, Quality and bioequivalence standards for narrow therapeutic index drugs, GPhA 2011 Fall Technical Workshop, Bethesda, Maryland, USA, Oct 1-2, 2012; http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM292676.pdf; last access date March 19, 2017.
    Search in Google ScholarBack to article
  3. 3. US Food&amp;Drug Administration, CFR - Code of Federal Regulations, Title 21 - Food and Drugs, Chapter I - Food and Drug Administration, Subchapter D - Drugs for Human Use, Part 320 - Bioavailability and Bioequivalence Requirements, Subpart B - Procedures for Determining the Bioavailability or Bioequivalence of Drug Products, Sec. 320.33 - Criteria and Evidence to Assess Actual or Potential Problems, Department of Health and Human Services, Silver Spring (MD) 2017, Vol. 5; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.33; last acces date March 19, 2017.
    Search in Google ScholarBack to article
  4. 4. J. Tamargo, J. L. Heuzey and P. Mabo, Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide, Eur. J. Clin. Pharmacol. 71 (2015) 549-567; <a href="https://doi.org/10.1007/s00228-015-1832-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s00228-015-1832-0</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1007/s00228-015-1832-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00228-015-1832-0</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmcid">4412688</dgpm:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">25870032</dgpm:pub-id>
    Search in Google ScholarBack to article
  5. 5. G. M. Currie, J. M. Wheat and H. Kiat, Pharmacokinetic considerations for digoxin in older people, Open Cardiovasc. Med. J. 5 (2011) 130-135; <a href="https://doi.org/10.2174/1874192401105010130" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.2174/1874192401105010130</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.2174/1874192401105010130" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2174/1874192401105010130</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmcid">3134946</dgpm:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">21769303</dgpm:pub-id>
    Search in Google ScholarBack to article
  6. 6. A. Yacobi, E. Masson, D. Moros, D. Ganes, C. Lapointe, Z. Abolfathi, M. LeBel, Y. Golander, D. Doepner, T. Blumberg, Y. Cohen and B. Levitt, Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin, J. Clin. Pharmacol. 40 (2000) 826-835; <a href="https://doi.org/10.1177/00912700022009558" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1177/00912700022009558</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1177/00912700022009558" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/00912700022009558</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">10934666</dgpm:pub-id>
    Search in Google ScholarBack to article
  7. 7. M. Bialer, R. H. Levy and E. Perucca, Does carbamazepine have a narrow therapeutic plasma concentration range? Ther. Drug Monit. 20 (1998) 56-59; <a href="https://doi.org/10.1097/00007691-199802000-00010" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1097/00007691-199802000-00010</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1097/00007691-199802000-00010" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/00007691-199802000-00010</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">9485555</dgpm:pub-id>
    Search in Google ScholarBack to article
  8. 8. J. Pesce, M. Rashkin and U. Kotagal, Standards of laboratory practice: theophylline and caffeine monitoring, Clin. Chem. 44 (1998) 1124-1128.
    Search in Google ScholarBack to article
  9. 9. J. W. Shin, K. Chu, K. H. Jung, S. T. Lee, J. Moon and S. K. Lee, Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations, Int. J. Clin. Pharmacol. Ther. 52 (2014) 1017-1022; <a href="https://doi.org/10.5414/CP202153" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.5414/CP202153</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.5414/CP202153" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.5414/CP202153</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">25295717</dgpm:pub-id>
    Search in Google ScholarBack to article
  10. 10. M. S. Paveliu, S. Bengea and F. S. Paveliu, Generic substitution issues: brand-generic substitution, generic-generic substitution, and generic substitution of narrow therapeutic index (NTI)/critical dose drugs, Maedica (Bucharest) 6 (2011) 52-58.
    Search in Google ScholarBack to article
  11. 11. Commonwealth of Pennsylvania, Generic Drug Equivalency/Substitution Laws and Regulations, Philadelphia (PA) April 1, 2017; https://apps.health.pa.gov/pdf/ddc/generic34.pdf; last access date June 21, 2017.
    Search in Google ScholarBack to article
  12. 12. W. C. Tom and K. Dotson, State regulations on generic substitution, Pharm. Lett. 22 (2006) Document# 220901.
    Search in Google ScholarBack to article
  13. 13. M. L. Chen, V. P. Shah, D. J. Crommelin, L. Shargel, D. Bashaw, M. Bhatti, H. Blume, J. Dressman, M. Ducharme, P. Fackler, T. Hyslop, L. Lutter, J. Morais, E. Ormsby, S. Thomas, Y. C. Tsang, R. Velagapudi and L. X. Yu, Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report, AAPS J. 13 (2011) 556-564; <a href="https://doi.org/10.1208/s12248-011-9294-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1208/s12248-011-9294-5</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1208/s12248-011-9294-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1208/s12248-011-9294-5</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmcid">3231855</dgpm:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">21845486</dgpm:pub-id>
    Search in Google ScholarBack to article
  14. 14. FDA@Drugs, Coumadin Label (2016); http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf; last access date March 19, 2017.
    Search in Google ScholarBack to article
  15. 15. A. R. Sheth, W. W. Brennessel, V. G. Young, F. X. Muller and D. J. Grant, Solid-state properties of warfarin sodium 2-propanol solvate, J. Pharm. Sci. 93 (2004) 2669-2680; <a href="https://doi.org/10.1002/jps.20164" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/jps.20164</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1002/jps.20164" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jps.20164</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">15389677</dgpm:pub-id>
    Search in Google ScholarBack to article
  16. 16. United States Pharmacopeia 39 - National Formulary 34, USP Convention, Rockville (MD) 2016.
    Search in Google ScholarBack to article
  17. 17. Z. Rahman, M. Korang-Yeboah, A. Siddiqui, A. Mohammad and M. A. Khan, Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product, Int. J. Pharm. 495 (2015) 19-30; <a href="https://doi.org/10.1016/j.ijpharm.2015.08.065" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.ijpharm.2015.08.065</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1016/j.ijpharm.2015.08.065" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijpharm.2015.08.065</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">26319638</dgpm:pub-id>
    Search in Google ScholarBack to article
  18. 18. A. Nguyenpho, A. B. Ciavarella, A. Siddiqui, Z. Rahman, S. Akhtar, R. Hunt, M. Korang-Yeboah and M. A. Khan, Evaluation of in-use stability of anticoagulant drug products: warfarin sodium, J. Pharm. Sci. 104 (2015) 4232-4240; <a href="https://doi.org/10.1002/jps.24657" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/jps.24657</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1002/jps.24657" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jps.24657</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">26501849</dgpm:pub-id>
    Search in Google ScholarBack to article
  19. 19. M. Korang-Yeboah, S. Akhtar, A. Siddiqui, Z. Rahman and M. A. Khan, Application of NIR chemometric methods for quantification of the crystalline fraction of warfarin sodium in drug products, Drug Dev. Ind. Pharm. 13 (2015) 1-11; <a href="https://doi.org/10.3109/03639045.2015.1058817" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3109/03639045.2015.1058817</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.3109/03639045.2015.1058817" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3109/03639045.2015.1058817</a></dgdoi:pub-id>
    Search in Google ScholarBack to article
  20. 20. A. Siddiqui, Z. Rahman, M. Korang-Yeboah and M. A. Khan, Development and validation of X-ray diffraction method for quantitative determination of crystallinity in warfarin sodium products, Int. J. Pharm. 493 (2015) 1-6; <a href="https://doi.org/10.1016/j.ijpharm.2015.07.051" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.ijpharm.2015.07.051</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1016/j.ijpharm.2015.07.051" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijpharm.2015.07.051</a></dgdoi:pub-id>
    Search in Google ScholarBack to article
  21. 21. Z. Rahman, A. A. Mohammad, S. Akhtar, A. Siddiqui, M. Korang-Yeboah and M. A. Khan, Chemometric model development and comparison of Raman and (13)C solid-state nuclear magnetic resonance-chemometric methods for quantification of crystalline/amorphous warfarin sodium fraction in the formulations, J. Pharm. Sci. 104 (2015) 2550-2558; <a href="https://doi.org/10.1002/jps.24524" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/jps.24524</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1002/jps.24524" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jps.24524</a></dgdoi:pub-id>
    Search in Google ScholarBack to article
  22. 22. C. F. Poole and S. K. Poole, Chromatography Today, Elsevier Science, Amsterdam 1991, pp. 133.
    Search in Google ScholarBack to article
  23. 23. C. A. Cramers, J. A. Rijiks and P. Bocek, Packed versus capillary columns in gas chromatography, Clin. Chim. Acta 34 (1971) 159-167; <a href="https://doi.org/10.1016/0009-8981(71)90169-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/0009-8981(71)90169-0</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1016/0009-8981(71)90169-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/0009-8981(71)90169-0</a></dgdoi:pub-id>
    Search in Google ScholarBack to article
  24. 24. E. Sarban, S. Socaci, M. Tofana, M. Simona and M. Bojita, Advantages of „headspace” technique for GC/MS analysis of essential oils, Farmacia 60 (2012) 249-256.
    Search in Google ScholarBack to article
  25. 25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, ICH, Geneva, November 2005; https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access March 19, 2017.
    Search in Google ScholarBack to article
  26. 26. A. Gupta, A. B. Ciavarella, V. A. Sayeed, M. A. Khan and P. J. Faustino, Development and application of validated HPLC method for the analysis of dissolution samples of gabapentin drug products, J. Pharm. Biomed. Anal. 46 (2008) 181-186; https://doi.org/org/10.1016/j.jpba.2007.08.023<dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1016/j.jpba.2007.08.023" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.jpba.2007.08.023</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">17935923</dgpm:pub-id>
    Search in Google ScholarBack to article
  27. 27. D. Awotwe-Otoo, C. Agarabi, P. J. Faustino, M. J. Habib, S. Lee, M. A. Khan, and R. B. Shah, Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate, J. Pharm. Biomed. Anal. 62 (2012) 61-67; <a href="https://doi.org/10.1016/j.jpba.2012.01.002" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jpba.2012.01.002</a><dgdoi:pub-id xmlns:dgdoi="http://degruyter.com/resources/doi-from-crossref" pub-id-type="doi"><a href="https://doi.org/10.1016/j.jpba.2012.01.002" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.jpba.2012.01.002</a></dgdoi:pub-id><dgpm:pub-id xmlns:dgpm="http://degruyter.com/resources/fetched-pubmed-id" pub-id-type="pmid">22316620</dgpm:pub-id>
    Search in Google ScholarBack to article
  28. 28. FDA, CDER, Reviewer Guidance - Validation of Chromatographic Methods, Rockville (MD) 1994; https://www.fda.gov/downloads/Drugs/Guidances/UCM134409.pdf; last access date March 19, 2017.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/acph-2018-0001 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 31 - 46
Accepted on: Oct 3, 2017
Published on: Feb 16, 2018
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
warfarin crystallinity,
isopropanol,
headspacegas chromatography
Related subjects:
Pharmacy,
Pharmacy, other

© 2018 Ziyaur Rahman, Sohail Akhtar, Akhtar Siddiqui, Anthony B. Ciavarella, Agnes Nguyenpho, Patrick J. Faustino, Mansoor A. Khan, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 68 (2018): Issue 1 (March 2018)Next article